Macrogen, a leading company in precision medicine and biotechnology, was established on June 5, 1997 based on the Genomic Medicine Institute of the Seoul National University College of Medicine. 

In February 2000, Macrogen became the first ever bio venture in Korea to be listed on the KOSDAQ. Since then, Macrogen has continued to be actively engaged in R&D fields of genetic and genomic analyses. Today, Macrogen has become a global expert in genomic analysis and a leader in Korean biotechnology, 

working closely with over 18,000 research clients across 153 countries worldwide. In addition to providing services to clients all over the world, Macrogen contributes to the advancement of bioindustries through a wide range of R&D and CSR activities.

Macrogen, an iconic Korean biotech company, is a global leader in genomic analysis

Founded on June 5, 1997, Macrogen Inc., has since emerged as a global leader in precision medicine and established as clients more than 18,000 research institutions in 153 countries around the world by constantly pursuing research and innovation in the cut-throat biotechnology industry. Equipped with unrivaled technological competence backed by top-class scientists, abundant research experience, and cutting-edge genomic analysis infrastructure, Macrogen offers its global customers base the best available biotech total solutions. For its high quality service, Macrogen has received ISO 9001 accreditation as well as CSP (certified service provider) certification from multiple genomic analysis platforms suppliers. Macrogen was also the first in the industry to obtain PIMS (personal information management system) certification for its outstanding effort to enhance information security and personal data protection. In addition, the company has done its best to share its cutting-edge technologies with others in the industry through constant technological cooperation with other leading gene sequencing companies.

Macrogen is preparing to take the next step forward – shifting from being a technology-centered company to a customer-centered company.

Utilizing its technological expertise and corporate status that it has built over the years, Macrogen now wants to shift its focus to growing its new customer-centered business by including things such as high value-added clinical diagnosis and personal genomics. To that end, Macrogen has already built its very own Precision Medicine Center network equipped with world-class clinical diagnostic laboratories and continues to develop and launch clinical diagnostic services based on the latest genomic analysis technologies for cancer diagnoses, among others. Furthermore, Macrogen has implemented localization strategies in key overseas markets through its US subsidiary (Psomagen, Inc.) and its subsidiaries in Europe and Japan in a bid to expand its global presence throughout the world with the launch of DTC genetic testing and microbiome analysis services. Macrogen pledges to continue exceling in both research activity and customer service in order to deliver customer satisfaction throughout the world while making progress towards being a biotechnology world leader with the most transparent and efficient business management practices in the industry as well. Thank you.